Importation, Internet Pharmacy Slated For Senate Aging Cmte. Hearing Jan. 26
This article was originally published in The Pink Sheet Daily
Executive Summary
Committee's first hearing under Chairman Gordon Smith (R-Ore.) will focus on risk/benefit issues with importation. Canada-only imports and the Bush Administration's recent task force report are among the likely topics.
You may also be interested in...
HHS Nominee Leavitt Wants To "Learn More" About Rx Imports
Michael Leavitt tells Senate Finance Committee during confirmation hearing that he has read "conflicting views" on the economic benefits of drug importation. Leavitt also notes that as HHS Secretary, importation safety issues would fall "squarely" on his desk.
AARP Will Continue To Support Dorgan/Snowe Drug Import Bill In 2005
The organization maintains that the Dorgan bill addresses the safety concerns contained in the HHS Importation Task Force report. AARP’s legislative agenda includes supporting proposals to make Medicaid more efficient and expanding its Medicare Rx awareness campaign.
HHS Import Report Gives No Ground: Savings Would Not Exceed 1%
Drug Importation Task Force Report suggests a limited, tightly regulated commercial import system is "feasible," but only if policymakers accept minimal savings and possible consequences on drug development. Report does not quantify costs of creating import system, but veto threat is explicit.